Human Genetics and Genomic Medicine by Lyon,  Gholson J. et al.
Human Genetics and Genomic Medicine  
Gholson Lyon 
with Max Doerfel, Jason O’Rawe, Yiyang Wu, Prashant Kota 
The Lyon laboratory focuses on analyzing human genetic variation and its role in severe 
idiopathic neuropsychiatric disorders. We do this by studying large pedigrees living in the same 
geographic location, where one can study the expressivity and segregation of variants in a 
similar environmental background and with fewer population stratification concerns. Toward this 
end, we collect pedigrees in Utah and elsewhere, and then utilize exome and whole genome 
sequencing to find mutations that segregate with syndromes in the pedigrees. We focus on the 
discovery of families with rare diseases and/or increased prevalence for syndromes such as 
intellectual disability, autism and schizophrenia.  
 
X-linked Malformation and Infantile Lethality Syndrome (provisionally named Ogden 
Syndrome) 
with Max Doerfel, Yiyang Wu, Thomas Arnesen (Norway) 
We have previously identified a lethal X-linked disorder of infancy comprising a distinct 
combination of distinctive craniofacial features producing an aged appearance, growth failure, 
hypotonia, global developmental delays, cryptorchidism, and acquired cardiac arrhythmias. The 
first family was identified in Ogden, Utah, with five affected boys in two generations of family 
members.  A mutation was identified as a c.109T>C (p.Ser37Pro) variant in NAA10, a gene 
encoding the catalytic subunit of the major human N-terminal acetyltransferase (NatA). This 
same mutation was identified in a second unrelated family, with three affected boys in two 
generations. This X-linked Malformation and Infantile Lethality Syndrome has provisionally been 
named Ogden Syndrome, in honor of the hometown where the first family resides. This is the 
first human disease involving a defect in the N-terminal acetylation of proteins, a common (yet 
vastly understudied) modifications of eukaryotic proteins carried out by N-terminal 
acetyltransferases (NATs). We are currently calling this new disease Ogden Syndrome, in honor 
of where the first family resides. There is significantly impaired biochemical activity of the mutant 
hNaa10p, suggesting that a reduction in acetylation of some unidentified proteins by hNaa10p 
might lead to this disease. There is currently very limited knowledge on the functional 
importance of Nt-acetylation at the protein level and at the organismal level. We have begun to 
study these processes in mammalian cell culture and yeast, along with setting up collaborations 
involving mice, zebrafish, and C. elegans. 
 
The Characterization and Analysis of an Idiopathic Intellectual Disability Syndrome via 
Whole Genome Sequencing Analysis 
with Jason O’Rawe, Yiyang Wu, Alan Rope and Jeffrey Swensen (University of Utah),  
We have delineated a new idiopathic syndrome with intellectual disability and distinctive 
facial dysmorphology. The propositi are two affected male brothers, aged 10 and 12 
respectively, with severe intellectual disability, autism-like behavior, attention deficit issues, and 
very distinctive facial features, including broad, upturned nose, sagging cheeks, downward 
sloping palpebral fissures, relative hypertelorism, high-arched palate, and prominent ears. Their 
parents are nonconsanguineous and are both healthy, and the family history does not 
demonstrate any other members with anything resembling this current syndrome. X-
chromosome inactivation assays reveal skewing in the mother, suggesting the possibility of an 
X-linked disorder. High-density genotyping arrays in the mother, father and two sons have not 
revealed previously known copy number variants (CNVs) that might contribute to the phenotype.  
Whole genome sequencing has led to the identification of several rare variants that are currently 
being characterized further, including in other unaffected members of the extended family. 
 
Expansion of collection efforts in Utah 
with Reid Robison and Clark Johnson (Utah Foundation for Biomedical Research), Kai Wang 
(University of Southern California, USC) 
 I have worked over the past year to collect dozens of additional families in Utah with severe 
neuropsychiatric disorders, as part of an Institutional Review Board (IRB)-approved protocol at 
the Utah Foundation for Biomedical Research (UFBR). We are collecting blood for DNA, RNA 
and peripheral blood mononuclear cells, with these cells to be used in future experiments to 
make and characterize induce pluripotent stem cells. For now, we are obtaining genotyping on 
the genomic DNA, and we have recently initiated whole genome sequencing of ~50 samples to 
a depth of >30x on the Illumina Hiseq platform, in an effort to understand the genetic basis of 
these disorders. The illnesses we are studying include intellectual disability, autism, 
schizophrenia, and other childhood-onset neuropsychiatric disorders. 
 
Toward more accurate variant calling for “personal genomes” 
with Jason O’Rawe, Yiyang Wu, Kai Wang (USC) 
To facilitate the clinical implementation of genomic medicine by next-generation 
sequencing, it will be critically important to obtain accurate and consistent variant calls on 
personal genomes. Multiple software tools for variant calling are available, but it is unclear how 
comparable these tools are or what their relative merits in real-world scenarios might be. We 
sequenced 15 exomes from four families using the Illumina HiSeq 2000 platform and Agilent 
SureSelect v.2 capture kit, with ~120X mean coverage. We analyzed the raw data using near-
default parameters with 5 different alignment and variant calling pipelines (SOAP, BWA-GATK, 
BWA-SNVer, GNUMAP, and BWA-SAMTools). We additionally sequenced a single whole 
genome using the Complete Genomics (CG) sequencing and analysis pipeline, with 95% of the 
exome region being covered by 20 or more reads per base. Finally, we attempted to validate 
919 SNVs and 841 indels, including similar fractions of GATK-only, SOAP-only, and shared 
calls, on the MiSeq platform by amplicon sequencing with ~5000X average coverage. SNV 
concordance between five Illumina pipelines across all 15 exomes is 57.4%, while 0.5-5.1% 
variants were called as unique to each pipeline. Indel concordance is only 26.8% between three 
indel calling pipelines, even after left-normalizing and intervalizing genomic coordinates by 20 
base pairs. 11% of CG variants that fall within targeted regions in exome sequencing were not 
called by any of the Illumina-based exome analysis pipelines. Based on targeted amplicon 
sequencing on the MiSeq platform, 97.1%, 60.2% and 99.1% of the GATK-only, SOAP-only and 
shared SNVs can be validated, but only 54.0%, 44.6% and 78.1% of the GATK-only, SOAP-only 
and shared indels can be validated.  Additionally, our analysis of two families, one containing 
four individuals and the other containing seven, demonstrates additional accuracy gained in 
variant discovery by having access to genetic data from a multi-generational family. Our results 
suggest that more caution should be exercised in genomic medicine settings when analyzing 
individual genomes, and to interpret positive and negative findings with scrutiny, especially for 
indels. Utilizing a combination of variants derived from multiple and orthogonal variant calling 
pipelines is a feasible first option for reducing false positives.  
 
Identifying disease mutations in genomic medicine settings: current challenges and how 
to accelerate progress 
with Kai Wang (USC) 
 The pace of exome and genome sequencing is accelerating, with the identification of 
many new disease-causing mutations in research settings, and it is likely that whole exome or 
genome sequencing could have a major impact in the clinical arena in the relatively near future. 
However, the human genomics community is currently facing several challenges, including 
phenotyping, sample collection, sequencing strategies, bioinformatics analysis, biological 
validation of variant function, clinical interpretation and validity of variant data, and delivery of 
genomic information to various constituents. In light of this, I worked with my collaborator Kai 
Wang on a comprehensive review of these challenges and summarizing the bottlenecks for the 
clinical application of exome and genome sequencing. We also suggested ways for moving the 
field forward, including the need for clinical-grade sample collection, high-quality sequencing 
data acquisition, digitalized phenotyping, rigorous generation of variant calls, and 
comprehensive functional annotation of variants.  Additionally, we suggested that a “networking 
of science” model that encourages much more collaboration and online sharing of medical 
history, genomic data and biological knowledge, including among research participants and 
consumers/patients, will help establish how certain mutations may contribute toward the 
development of certain phenotypes.  
 
A proposal for an Analytic-Interpretive split (or a so-called “distributive model”) across 
both clinical and research genomics.   
with Jeremy Segal (New York Genome Center) 
I have been working on a policy piece related to the field of clinical genomics. In brief, 
the United States federal government mandates that any laboratory performing tests on human 
specimens “for the purpose of providing information for the diagnosis, prevention, or treatment 
of any disease” must satisfy the conditions set forth in the Clinical Laboratory Improvement 
Amendments (CLIA) of 1988.  Most laboratories in academic research settings do not have 
sufficient standards in place to qualify them for CLIA approval.  At the time CLIA was enacted, 
the separation of the clinical and research worlds seemed a fairly straightforward proposition.  
But today, the issues we face from a regulatory and ethical standpoint around genomics stem 
from the simple question: what do we do when it becomes difficult to draw a clear line of 
distinction between these two types of laboratory practices, particularly when researchers are 
working directly with families? Families afflicted with rare genetic disorders now have a 
reasonable expectation of definitive and potentially actionable results on the order of days to 
months, and all such families regardless of diagnosis are candidates for a relatively 
standardized genomic (rather than disease-specific mechanistic) analysis.  The situation is 
similar for with cancer, as standardized tumor-agnostic genomic analyses have a high likelihood 
of uncovering plausible drug targets during the lifetimes of some people, even those with late-
stage disease. Some in the field might argue for the continued suitability of the “research first, 
clinical follow-up” model, with Sanger sequencing confirmation of “medically actionable” 
variants. But looking forward, as we learn more and more from the genome, and depending 
upon what types of data individuals want to receive from their genomes, the number of variants 
requiring confirmation will only increase, perhaps substantially.  At $300 per variant (which is 
Sanger-based CLIA gene testing and unlikely to change anytime soon), the research model 
may rapidly become prohibitively expensive when used to manage care. Clearly history has 
shown that the quality of unregulated diagnostics is susceptible to perverse market forces, as 
many prior poor practices can be tied directly to economic conflicts of interest.  At a minimum, 
CLIA erects standards to protect laboratories from these forces and provides an enforcement 
structure.  The field would be prudent to embrace this protection, in light of the ongoing 
commoditization of sequencing and its associated potential for severe price competition.  
As a solution, we are proposing an analytic-interpretive split (or a so-called “distributive 
model”) across clinical genomics.  This split model simply means that one laboratory performs 
sample processing/sequencing and then downstream laboratories can perform the interpretation 
and reporting.  Thus, together, the laboratories perform all the functions that make up a 
laboratory test.  The practical effect of this split would be to turn an exome or genome sequence 
into a discrete deliverable clinical unit that could be used for multiple purposes by downstream 
labs. The raw data, if individually approved, could be uploaded to electronic health records or 
others online sources, allowing its use in downstream investigative analysis. Another overlooked 
benefit of performing more standardized genome sequencing would be its effect on resultant 
datasets, and the community’s resultant confidence therein. Enacting the type of split described 
herein allows organizations to leverage their strengths in sequencing or bioinformatics, thus 
lowering costs across the entire process.  It will also help to provide guidance to the many 
rapidly proliferating laboratories devoted to clinical genomic data mining.  However, it is 
essential that we think of these companies as laboratories, even if they may be separate from 
the wet lab.  Their post-analytic processing would simply be an extension of a prior wet-lab 
process, and thus included as a core component of a medical test.  
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